Clinical Trials Logo

Salivary Gland Neoplasms clinical trials

View clinical trials related to Salivary Gland Neoplasms.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05694819 Active, not recruiting - Clinical trials for Salivary Gland Cancer

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Start date: April 17, 2020
Phase: Phase 2
Study type: Interventional

This study is an open-label phase 2 study to evaluate the safety and efficacy of Darolutamide monotherapy in patients with androgen receptor-positive salivary gland carcinoma. Moreover, this study will evaluate the safety and efficacy of Darolutamide and Goserelin combination in patients with androgen receptor-positive salivary gland carcinoma.

NCT ID: NCT05581979 Active, not recruiting - Clinical trials for Salivary Gland Tumor

PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers

Start date: January 26, 2022
Phase:
Study type: Observational

The objectives of this pilot feasibility study, which is on the use of 68-Ga PSMA PET imaging of salivary gland tumours, are - to determine the proportion of patients with high PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancer; and - to determine if in vitro PSMA expression correlates to PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancers. The hypotheses of this study are that there is high PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancers; and that in vitro PSMA expression correlates to PSMA-ligand uptake on Ga-68 PSMA imaging.

NCT ID: NCT05010629 Active, not recruiting - Metastatic Cancer Clinical Trials

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Start date: September 14, 2021
Phase: Phase 2
Study type: Interventional

This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: - 9-ING-41 (a GSK-3β inhibitor) - Carboplatin chemotherapy

NCT ID: NCT05008237 Active, not recruiting - Clinical trials for Salivary Gland Cancer

Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study

Start date: May 2, 2014
Phase: Phase 2
Study type: Interventional

Cisplatin plus weekly docetaxel as first-line chemotherapy in metastatic salivary gland cancer patients : a multicenter phase II study

NCT ID: NCT04576091 Active, not recruiting - Clinical trials for Recurrent Head and Neck Squamous Cell Carcinoma

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Start date: July 6, 2022
Phase: Phase 1
Study type: Interventional

This phase I trial evaluates the best dose, possible benefits and/or side effects of combination therapy with elimusertib (BAY 1895344), stereotactic body radiation, and pembrolizumab in treating patients with head and neck squamous cell cancer that has come back (recurrent) and cannot be removed by surgery (unresectable). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving BAY 1895344, stereotactic body radiation therapy in combination with pembrolizumab may shrink or stabilize head and neck squamous cell cancer for longer than treatment with radiation and immunotherapy without BAY 1895344.

NCT ID: NCT04325828 Active, not recruiting - Clinical trials for Salivary Gland Neoplasms

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma

YATAGARASU
Start date: April 7, 2020
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the overall response rate (ORR) of apalutamide in combination with a gonadotropin-releasing hormone (GnRH) agonist in participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC).

NCT ID: NCT04249947 Active, not recruiting - Prostate Cancer Clinical Trials

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Start date: February 28, 2020
Phase: Phase 1
Study type: Interventional

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

NCT ID: NCT03781986 Active, not recruiting - Clinical trials for Salivary Gland Cancer

APG-115 in Salivary Gland Cancer Trial

Start date: October 28, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II trial to evaluate the efficacy of APG-115 +/- Carboplatin for the treatment p53 wild-type malignant salivary gland cancer. Part 1 consisted of 2 arms, arm A (APG-115 monotherapy) and arm B (APG-115 + Carboplatin) and was terminated early. Part 2 is a single arm study (APG-115 monotherapy).

NCT ID: NCT03172624 Active, not recruiting - Clinical trials for Salivary Gland Cancer

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Start date: May 26, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.

NCT ID: NCT03146650 Active, not recruiting - Clinical trials for Recurrent Salivary Gland Carcinoma

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Start date: May 19, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies the efficacy (the effect on the tumor) and the safety (the effect on the body) of the study drugs when given as a combination in participants with this type of cancer. Another purpose of the study is to see which tumor markers (proteins in the blood that the body produces in response to the cancer) lead to better results in participants treated with the study drugs. Nivolumab and ipilimumab are antibodies, which are human proteins that recognize and attach to a part of the tumor and/or body's immune cells. They work in slightly different ways to activate the immune system and help the body's immune system to work against tumor cells. Nivolumab and ipilimumab are investigational because they are not approved by the FDA to be used for the type of cancer being studied.